STOCK TITAN

PainReform Ltd. Ordinary Shares - PRFX STOCK NEWS

Welcome to our dedicated page for PainReform Ltd. Ordinary Shares news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PainReform Ltd. Ordinary Shares stock.

PainReform Ltd. (symbol: PRFX) is a clinical-stage specialty pharmaceutical company dedicated to the development of innovative pain management solutions. The company focuses on the reformulation of established pain therapeutics, leveraging the US FDA 505(b)(2) regulatory pathway to bring enhanced products to market more efficiently.

The company’s flagship product, PRF-110, is designed to address the significant need for localized and extended post-operative pain relief. PRF-110 is a unique, oil-based, viscous solution containing the local anesthetic ropivacaine. This solution is applied directly into the surgical wound bed before closure, providing sustained pain relief and reducing the need for additional analgesics post-surgery.

PainReform applies proprietary technologies to improve the efficacy, reduce the adverse effects, and increase the convenience of pain medications. Their mission is to deliver pain therapeutics that offer clinically meaningful benefits to both physicians and patients.

Recent Achievements: PRF-110 has demonstrated superior formulation properties, particularly in terms of surface-tissue spreading, which is crucial for effective localized pain management. The company remains on track to announce top-line data from their clinical trials by mid-2024, indicating significant progress in their development timeline.

PainReform Ltd. continues to build strategic partnerships and collaborations to advance its product pipeline and bring new pain management solutions to market. By focusing on the reformulation of established drugs, the company aims to enhance patient outcomes and contribute positively to the field of pain management.

Rhea-AI Summary

PainReform Ltd. (Nasdaq: PRFX) announced a private placement to raise approximately $6.0 million by issuing 1,304,346 ordinary shares and warrants. The purchase price is set at $4.60 per share, with warrants allowing the purchase of an additional 652,173 shares. Closing is expected on March 10, 2021, pending customary conditions. Maxim Group LLC and Joseph Gunnar & Co., LLC are acting as placement agents. The securities will not be registered under the Securities Act and are offered only to accredited investors. This move highlights PainReform's strategy to secure funding for its pain relief product, PRF-110.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
none
-
Rhea-AI Summary

PainReform Ltd. (Nasdaq: PRFX), a clinical stage specialty pharmaceutical company, announced participation in the H.C. Wainwright BioConnect 2021 Conference, occurring virtually from January 11-14, 2021. A webcast of the presentation will be available on-demand starting January 11, 2021, at 6:00 a.m. ET, accessible for 90 days. PainReform's lead product, PRF-110, aims to enhance post-operative pain relief using a proprietary extended-release drug-delivery system, targeting the local anesthetic market with reduced opiate needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
conferences
-
Rhea-AI Summary

PainReform Ltd. (Nasdaq: PRFX) has appointed Rita Keynan as Vice President of Pharmaceutical Operations. With over 25 years in the pharmaceutical sector, Keynan has a solid background in drug development, overseeing all facets from early trials to NDA filings. Her prior role was with VYNE Therapeutics, managing a team focused on drug development. CEO Ilan Hadar expressed confidence in her capabilities as the company prepares for Phase 3 trials of their lead product, PRF-110, aimed at post-operative pain relief through an innovative drug-delivery system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.16%
Tags
management
Rhea-AI Summary

PainReform Ltd. (NasdaqCM:PRFX) announced the appointment of Lotus Clinical Research as its CRO for the upcoming Phase 3 trial of PRF-110. This trial will focus on patients undergoing bunionectomy and hernia repair operations. LCR is specialized in analgesic studies, with a history of approximately 350 trials resulting in over ten approvals. Previous Phase 2 results showed PRF-110 provided pain relief for up to 72 hours, outperforming ropivacaine's 2-6 hours. The CEO stated confidence in the trial's design, aiming to address the opioid crisis while demonstrating safer pain relief options.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
management clinical trial
-
Rhea-AI Summary

PainReform Ltd. (NASDAQ:PRFX) has appointed Ilan Hadar as its new CEO, effective immediately. With over 20 years in the pharmaceutical sector, Hadar has led operations and developed products in the U.S. and Israel. His previous roles include serving as Country Manager and CFO at Foamix Pharmaceuticals and Finance Director at Pfizer. The appointment comes as PainReform prepares for pivotal Phase 3 trials for its lead product PRF-110, aimed at changing post-operative pain management by reducing reliance on opioids.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.34%
Tags
management
-
Rhea-AI Summary

PainReform Ltd. (NASDAQ:PRFX) has appointed Dr. Ellen Baron to its Board of Directors, enhancing its leadership after a recent IPO. Dr. Baron brings over 20 years of experience in the healthcare and capital markets sectors, previously holding key positions at Outcome Capital LLC and Healthios Capital Markets. Her expertise in business development and clinical affairs will be pivotal as PainReform advances its PRF-110 drug through Phase 3 trials aimed at the post-operative pain relief market. The company is optimistic about its future growth potential, targeting a significant market opportunity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
management
Rhea-AI Summary

PainReform Ltd. (NASDAQ:PRFX) has appointed Augustine Lawlor to its Board of Directors following its recent IPO. Lawlor, with extensive experience in the pharmaceutical sector, previously served as COO of Leap Therapeutics and held key positions at LeukoSite and Alpha-Beta Technologies. His expertise includes finance, business development, and mergers and acquisitions, making him a valuable addition as PainReform advances its lead product, PRF-110, through Phase 3 trials. This product aims to revolutionize post-operative pain management while potentially reducing reliance on opioids.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
management
-
Rhea-AI Summary

PainReform Ltd. (NASDAQCM:PRFX) provided updates on its lead drug candidate PRF-110, demonstrating unique surgical benefits beyond pain relief. Studies showed PRF-110 does not affect suture integrity or wound healing, targeting the post-operative pain market. The drug offers up to 72 hours of pain reduction with no serious adverse events reported. As PainReform advances into Phase 3 studies for bunionectomy and hernia repair, the company believes PRF-110 could significantly alter post-surgical practices and address the opioid crisis, potentially capturing a share in the $12 billion market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.61%
Tags
none
-
Rhea-AI Summary

PainReform Ltd. (NASDAQ:PRFX) has initiated preparations for pivotal Phase 3 clinical trials of PRF-110, aimed at treating post-operative pain, following a successful initial public offering that raised $20 million. The FDA has granted an IND for PRF-110, supported by positive Phase 2 results. The trials are designed to be brief, with primary endpoints based on a standard pain scale. PRF-110, a clear, viscous solution containing the well-known anesthetic ropivacaine, is intended to provide localized and extended pain relief, potentially reducing opiate use. The post-operative pain market is projected to grow from $12 billion to over $45 billion by 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

PainReform Ltd. (NASDAQ:PRFX) closed its initial public offering on September 3, 2020, offering 2,500,000 units at $8.00 each, yielding approximately $20 million before expenses. Each unit comprises one Ordinary Share and one Warrant for an additional share, separable upon issuance. The Ordinary Shares began trading on Nasdaq on September 1, 2020. Underwriters have a 45-day option to purchase up to 375,000 additional shares or warrants to cover over-allotments. PainReform focuses on reformulating established therapeutics, with its lead product PRF-110 targeting post-operative pain relief.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags

FAQ

What is the current stock price of PainReform Ltd. Ordinary Shares (PRFX)?

The current stock price of PainReform Ltd. Ordinary Shares (PRFX) is $5.3 as of December 20, 2024.

What is the market cap of PainReform Ltd. Ordinary Shares (PRFX)?

The market cap of PainReform Ltd. Ordinary Shares (PRFX) is approximately 4.3M.

What is PainReform Ltd.?

PainReform Ltd. is a clinical-stage specialty pharmaceutical company focused on developing reformulated pain management therapeutics.

What is PRF-110?

PRF-110 is PainReform Ltd.'s lead product, an oil-based solution containing ropivacaine for localized post-operative pain relief.

How does PRF-110 work?

PRF-110 is applied directly into the surgical wound bed before closure, providing extended localized analgesia.

What are the benefits of using PRF-110?

PRF-110 aims to enhance pain relief, reduce adverse effects, and increase convenience for post-operative pain management.

What regulatory pathway does PainReform Ltd. use?

PainReform Ltd. utilizes the US FDA 505(b)(2) regulatory pathway for the reformulation of established pain drugs.

When will PainReform announce top-line data for PRF-110?

PainReform is expected to announce top-line data from its PRF-110 clinical trials by mid-2024.

What are the recent achievements of PainReform Ltd.?

PRF-110 has shown superior surface-tissue spreading properties and is on track to deliver significant clinical data by mid-2024.

What is PainReform Ltd.'s mission?

PainReform's mission is to provide pain therapeutics with clinically meaningful benefits for both physicians and patients.

How does PainReform Ltd. enhance its products?

The company uses proprietary technologies to improve drug efficacy, reduce side effects, and increase convenience.

What market is PRF-110 targeting?

PRF-110 targets the post-operative pain relief market.

PainReform Ltd. Ordinary Shares

Nasdaq:PRFX

PRFX Rankings

PRFX Stock Data

4.25M
846.29k
2.52%
9.74%
5.23%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Tel Aviv